{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Teprotumumab has the potential to meet these requirements by specifically blocking the', 'autoimmune pathophysiology thought to underlie active TED.', '7.1.2 Insulin-like Growth Factor-1 Receptor (IGF-1R)', \"The key underlying mechanism in Graves' hyperthyroidism is the generation of auto-antibodies\", \"(Grave' Disease immunoglobulin G; GD-IgGs) that act on the thyroid to produce\", 'hyperthyroidism [Akamizu, 2001]. The primary molecular mechanism through which GD-IgGs', 'produce hyperthyroidism is believed to be activation of thyroid stimulating hormone receptors', '(TSHR) in thyroid follicular cells [Akamizu, 2001]. TED also has an autoimmune basis, but in', 'this case, the primary cellular target appears to be orbital fibroblasts. GD-IgGs stimulate orbital', 'fibroblasts to proliferate, release cytokines, initiate an inflammatory response, differentiate into', 'adipocytes and myofibroblasts, and to secrete excessive amounts of extracellular matrix (e.g.,', 'hyaluronan), which in turn results in fibrosis and edema [Smith, 2010]. It was initially assumed', \"that, as with Graves' hyperthyroidism, GD-IgGs produced TED through activation of TSHR.\", 'However, the data for this has never been definitive and a number of lines of evidence argue', 'against there being a single, common molecular target for the 2 conditions. For example, it is not', \"uncommon for there to be longitudinal misalignments in the time courses of Graves'\", 'hyperthyroidism and TED; approximately 10% of TED patients never become hyperthyroid and', 'some TED patients experience unilateral eye symptoms. Moreover, there is disagreement in the', 'literature about whether the levels of TSHR expressed in orbital tissues are alone sufficient to', 'trigger and drive TED (e.g., [Bahn, 2010; Boschi et al, 2005; Smith et al, 2004]).', 'There are no well-established animal models for TED, and this has hampered both the study of', 'mechanism and the discovery of novel therapeutics. Nevertheless, evidence is now accumulating', 'that TSHR may not be the only autoantigen that is involved in regulating TED pathology.', 'Specifically, a substantial body of data has been generated arguing that the insulin-like growth', 'factor-1 receptor (IGF-1R) plays an important role in regulating the pathophysiological', 'responses produced in orbital an immune cells by GD-IgGs. Key nonclinical data supporting the', 'involvement of IGF-1R in the mechanism of active TED are:', '1. IGF-1R is localized on orbital fibroblasts and binding of IGF to fibroblasts can be', 'displaced by GD-IgGs [Weightman et al, 1993].', '2. IGF-1R is up-regulated in cultured orbital fibroblasts from patients with TED, while', 'TSHR is only expressed at low levels [Tsui et al, 2008].', '3. Stimulation of IGF-1R by GD-IgGs in orbital fibroblasts from patients with TED causes', 'increased release of the T-cell attracting cytokines IL-16 and RANTES [Pritchard et al,', '2003]. Importantly, this effect of GD-IgGs is fully reversed by a monoclonal antibody', '(mAb) antagonist specific for IGF-1R.', '4. IGF-1 and GD-IgGs increase hyaluronan synthesis in orbital fibroblasts from patients', 'with TED, but not in orbital fibroblasts from control subjects or dermal fibroblasts [Smith', 'et al, 2004]. Again, this effect of GD-IgGs is blocked by a selective IGF-1R antagonist', 'antibody. Interestingly, in these studies thyroid stimulating hormone (TSH) failed to', 'stimulate hyaluronan synthesis in orbital fibroblasts from patients with TED.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 48 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '5. IGF-1R expression is increased on both T-cells and B-cells from patients with TED,', 'providing additional, immune-based mechanisms through which GD-IgGs acting on', 'IGF-1R would promote an inflammatory response [Douglas et al, 2007; Douglas et al,', '2008].', '6. A recent microarray genomics study, using orbital fat samples from TED patients,', 'showed that active disease has a marked dysregulation of genes in the IGF/IGF-1R', 'signaling pathway [Ezra et al, 2011].', '7. Experiments with human orbital fibroblasts and thyrocytes suggest that IGF-1R is', 'physically associated with TSHR. Moreover, inhibiting IGF-1R with an antagonist', 'antibody also has the effect of reducing signaling through TSHR [Tsui et al, 2008].', 'Remarkably, this work suggests that the 2 major autoantigens implicated in TED are', 'physically and functionally coupled.', '7.1.3 Teprotumumab', 'Teprotumumab (HZN-001) is a fully human immunoglobulin G1 (IgG1) mAb directed against', 'human IGF-1R. The IGF-1R is a tyrosine kinase cell surface receptor that shares ~50% overall', 'homology with the insulin receptor [Ullrich et al, 1986]. Teprotumumab binds with high affinity', 'and selectivity to the extracellular domain of IGF-1R and prevents its activation by the', 'endogenous ligands, IGF-1 and IGF-2. Teprotumumab has no partial agonist activity at IGF-1R,', 'as assessed by activation of the canonical signaling pathway (phosphoinositide 3 kinase/Akt),', 'and has no affinity for the insulin receptor. In addition, teprotumumab causes direct inactivation', 'of IGF-1R through antibody-induced cellular internalization and degradation. Binding of', 'teprotumumab has been shown to inhibit canonical signal transduction and cellular proliferation', 'and survival functions mediated by IGF-1R in cancer cells. Teprotumumab does not induce', 'antibody-dependent cellular cytotoxicity.', 'Teprotumumab was originally developed by F. Hoffman-La Roche, Ltd., for the treatment of', 'subjects with advanced solid tumors, including sarcoma. In vitro and in vivo studies suggest that', 'IGFs play important roles in the development and progression of cancer. Details of the', 'development of the compound (previously identified as RO4858696 or R1507) in the oncology', \"indication are provided in the Horizon Investigator's Brochure (IB) [Investigator's Brochure,\", 'Edition 7.0, 07 July 2017]. Roche is no longer pursuing development of teprotumumab in', 'oncology indications. Development was terminated due to inadequate efficacy in cancer', 'indications, not to any observed side effects or safety issues.', 'River Vision Development Corporation licensed teprotumumab for development in the orphan', 'indication of TED. Horizon Pharma acquired River Vision Development Corporation in May of', '2017 and will continue the development of teprotumumab for TED.', '7.1.3.1 Physiochemical Properties', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 49 of 117']\n\n###\n\n", "completion": "END"}